Hosted on MSN1h
NICE green lights two blood cancer therapies for NHS use
BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...
stocknews3h
3 Precision Medicine Stocks That Could Transform Healthcare
With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...
JD Supra3h
Top Legal Challenges for the Health Care Industry in 2025
With 2025 underway, the AFS Health Care team highlights some of the most pressing legal issues facing the health care industry this year.
Healthcare sector takes the lead in 2025 as market volatility rises
The Healthcare sector of the economy is front and center on Friday as shares of UnitedHealth drop 7.8%, spurring a widespread market selloff across the broader market a ...
Bristol-Myers Squibb (BMY) Gets a Hold from Bernstein
Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...
Hosted on MSN13h
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
Medscape14h
Bladder Cancer Survival Better With Nivolumab Than Placebo in New Analysis
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...